Abstract |
In the treatment of group A beta-hemolytic streptococcal pharyngitis, penicillin is the drug of choice and erythromycin is the alternative. In a double-blind, randomized study, dirithromycin, a new macrolide, was compared with penicillin for the treatment of streptococcal pharyngitis. Of 121 patients who were treated with dirithromycin, 96.7% manifested a favorable clinical response, and of 136 patients treated with penicillin, 94.2% manifested a favorable clinical response. Streptococci were eradicated from the pharynges of 85.3% of 116 dirithromycin-treated patients and 82.5% of 126 penicillin-treated patients who returned for follow-up. There were no statistically significant differences in efficacy between the two groups. The incidence of abdominal symptoms was higher in dirithromycin-treated patients. Being as efficacious as penicillin and having the advantages over erythromycin of once-daily dosing and the lack of drug interactions, dirithromycin is an alternative to penicillin in the treatment of streptococcal pharyngitis for patients 12 years of age and older.
|
Authors | V S Watkins, M Smietana, P M Conforti, G D Sides, W Huck |
Journal | Antimicrobial agents and chemotherapy
(Antimicrob Agents Chemother)
Vol. 41
Issue 1
Pg. 72-5
(Jan 1997)
ISSN: 0066-4804 [Print] United States |
PMID | 8980757
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Anti-Bacterial Agents
- Macrolides
- Penicillins
- dirithromycin
- Erythromycin
|
Topics |
- Adolescent
- Adult
- Anti-Bacterial Agents
(therapeutic use)
- Double-Blind Method
- Drug Therapy, Combination
(therapeutic use)
- Erythromycin
(analogs & derivatives, therapeutic use)
- Female
- Humans
- Macrolides
- Male
- Penicillins
(therapeutic use)
- Pharyngitis
(drug therapy, microbiology)
- Streptococcal Infections
(drug therapy, microbiology)
- Streptococcus pyogenes
(drug effects)
- Treatment Outcome
|